Comparison of colloidal bismuth subcitrate and metronidazole, both in combination with an H2-antagonist as therapy for Helicobacter pylori.
In this random study, the efficacy of either colloidal bismuth subcitrate (CBS) or metronidazole in combination with an H2-antagonist in the treatment of various gastric pathologies was evaluated, along with the trends in antibody levels. Among the 40 Helicobacter pylori-positive patients with various gastroduodenal pathologies who underwent chemotherapy, 27 were treated with CBS and 13 with metronidazole. H. pylori was eradicated in 48.14% of the patients treated with CBS and 53.8% of those treated with metronidazole. After therapy, no statistically significant or slight decrease in the serum levels of antibodies was found.
Baffone
W
W
Institute of Toxicologic, Hygienic and Environmental Sciences, University of Urbino, Italy.
Belbusti
F
F
Barbieri
E
E
Pianetti
A
A
Bruscolini
F
F
Fabi
M T
MT
Salvaggio
L
L
Albano
A
A
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D008795:Metronidazole / Q000627:therapeutic use*; D008875:Middle Aged; D009942:Organometallic Compounds / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D009942:Organometallic Compounds; D008795:Metronidazole; C002791:bismuth tripotassium dicitrate